Compare Ascendis Pharma A/S (ASND) vs Infosys Limited (INFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Infosys Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Infosys Limited trades at $11.19 (market cap $45.83B). The key difference: Infosys Limited is far larger — about 2.6× Ascendis Pharma A/S's market cap, and Infosys Limited pays a 4.79% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | INFY | |
|---|---|---|
Market Cap | $17.74B | $45.83B |
Sector | Health | Technology |
52-Week High | $277.18 | $20.22 |
52-Week Low | $163.32 | $10.49 |
Enterprise Value | $18.11B | $43.05B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
INFY trades at $10.94, down 1.71% for the day, with technical indicators showing a bearish trend. The company maintains strong profitability with 16.44% net margins and 31.57% ROE, though recent earnings show mixed results with one miss and two beats. Recent news highlights INFY's aggressive AI partnerships across healthcare, banking, and media sectors, positioning the company for digital transformation leadership.
The stock presents a valuation opportunity with P/E of 13.68 below industry averages, supported by analyst consensus target of $12.14 (11% upside). Key risks include competitive pressures in IT services and potential margin compression from AI investments. Current institutional sentiment leans neutral with 52.5% hold ratings amid transitional business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
